valsartan and Acute Disease

Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Chronic Disease; Defibrillators, Implantable; Diuretics; Drug Combinations; Extracorporeal Membrane Oxygenation; Guideline Adherence; Heart Failure; Heart-Assist Devices; Infusions, Intravenous; Iron; Tetrazoles; Valsartan

Topics: Acute Disease; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Combined Modality Therapy; Drug Combinations; Heart Failure, Diastolic; Heart Failure, Systolic; Humans; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Spironolactone; Survival Rate; Tetrazoles; Valsartan

Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan

Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Pyridazines; Tetrazoles; Valine; Valsartan; Vasodilator Agents

Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Discharge; Peptide Fragments; Tetrazoles; Valsartan

Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arterial Pressure; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Hormone Antagonists; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; Pulmonary Artery; Stroke Volume; Tetrazoles; Treatment Outcome; Troponin T; Valsartan

Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Discharge; Patient Readmission; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Output, Low; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan

Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan

Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

Topics: Acute Disease; Aminobutyrates; Angiotensin Receptor Antagonists; Anti-Retroviral Agents; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Middle Aged; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Pressure

Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan

Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Electrocardiography; Humans; Male; Middle Aged; Models, Cardiovascular; Myocardium; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

Topics: Acute Disease; Adenosine Diphosphate; Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Heart; In Vitro Techniques; Intracellular Membranes; Membrane Potentials; Mitochondria, Heart; Myocardial Ischemia; Oxidative Phosphorylation; Oxygen Consumption; Rats; Rats, Wistar; Tetrazoles; Time Factors; Valine; Valsartan

Topics: Acute Disease; Animals; Antihypertensive Agents; Blood Flow Velocity; Chemoprevention; Endothelium; Fosinopril; H(+)-K(+)-Exchanging ATPase; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Swine; Tetrazoles; Time Factors; Valine; Valsartan

Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cell Adhesion Molecules; Cell Communication; Cells, Cultured; Disease Models, Animal; Fibroblasts; Gene Expression Regulation; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Random Allocation; Rats; Rats, Inbred Lew; Rats, Wistar; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Remodeling

Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Female; Hemodynamics; Ischemia; Kidney Glomerulus; Microcirculation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renal Circulation; Reperfusion Injury; Tetrazoles; Valine; Valsartan

Topics: Acute Disease; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Middle Aged; Tetrazoles; Valine; Valsartan